Life Technologies Launches CE-IVD Marked QuantStudio™ Dx Real-Time PCR Instrument in Europe

Life Technologies Launches CE-IVD Marked QuantStudio™ Dx Real-Time PCR Instrument in Europe PR Newswire CARLSBAD, California, November 19, 2012 CARLSBAD, California, November 19, 2012 /PRNewswire/ -- Flagship qPCR instrument offers reliability, accuracy, ease of use and flexibility for IVD and lab-developed diagnostic tests Life Technologies Corporation (NASDAQ:LIFE) today announced the launch of its Applied Biosystems QuantStudio™ Dx Real-Time PCR Instrument designed to meet the specific needs of clinical diagnostic laboratories. The instrument is CE-IVD marked for use in Europe and represents a significant extension of Life Technologies' product offerings in the diagnostics arena. Life Technologies Corporation "Molecular diagnostic tests based on real-time PCR have become indispensable to the clinical lab," said Ronnie Andrews, president of Medical Sciences at Life Technologies. "Molecular testing is the fastest-growing segment of the diagnostics market, and the QuantStudio™ Dx instrument has unique features that will allow us to capture that market growth." The global IVD (in vitro diagnostic) market is approximately $52 billion and is expected to reach $70 billion by 2015. [1]The current European IVD market is approximately $14 billion and expected to reach $17 billion by 2015.